Document is current
Any future updates will be listed below
-
Authors
Matsumoto, Akihiro
Nishiguchi, Shuhei
Enomoto, Hirayuki
Tanaka, Yasuhito
Shinkai, Noboru
Okuse, Chiaki
Kang, Jong-Hon
Matsui, Takeshi
Miyase, Shiho
Yatsuhashi, Hiroshi
Nagaoka, Shinya
Kanda, Tatsuo
Enomoto, Masaru
Yamada, Ryoko
Hiramatsu, Naoki
Saito, Satoru
Takaguchi, Koichi
Ito, Kiyoaki
Masaki, Tsutomu
Morihara, Daisuke
Tsuge, Masataka
Chayama, Kazuaki
Ikeda, Fusao
Kagawa, Tatehiro
Kondo, Yasuteru
Murata, Kazumoto
Tanaka, Eiji https://orcid.org/0000-0002-0724-2104
-
Funding
Funding for this research was provided by:
The Japan Agency for Medical Reserch and Developement (17fk0210306h003)
The Japan Agency for Medical Research and Development (JP18fk0210034)
- License Information
-
More Information
Article History
Received: 12 March 2020
Accepted: 25 June 2020
First Online: 14 July 2020
Conflict of interest
: Yasuhito Tanaka received honoraria from FUJIREBIO and Gilead Sciences. Yasuhito Tanaka also received research funding from FUJIFILM, Board of Trustees of the Leland Stanford Junior University, and GlaxoSmithKline; Chiaki Okuse received honoraria from AbbVie; Hiroshi Yatsuhashi received research funding from Abbvie; Naoki Hiramatsu received honoraria from Gilead Sciences; Koichi Takaguchi received honoraria from AbbVie, Gilead Sciences, Otsuka, and Eizai; Kiyoaki Ito received research funding from AbbVie and Gilead Sciences; Kazuaki Chayama received honoraria from Dainippon Sumitomo, Otsuka, Gilead, Bristol-Myers Squibb, AbbVie, MSD, Ajinomoto, Eisai, Toray, Chugai, Daiichi Sankyo, and Takeda. Kazuaki Chayama also received research funding from Dainippon Sumitomo, Otsuka, Gilead, Bristol-Myers Squibb, AbbVie, MSD, Eisai, Toray, Daiichi Sankyo, and Takeda; Tatehiro Kagawa received honoraria from AbbVie, Sumitomo Dainippon Pharma, Bayer, Eisai, Gilead Sciences. Tatehiro Kagawa also received research funding from AbbVie, Sumitomo Dainippon Pharma, Bayer, Eisai, Daiichi Sankyo; Kazumoto Murata received honoraria from Gilead Sciences; Eiji Tanaka received honoraria from Gilead Sciences and MSD. Eiji Tanaka also received research funding from AbbVie, Astellas, and Otsuka.
